Description

Retatrutide Nasal Spray

Retatrutide
CAS Number	2381089-83-2
Molar Mass	4731.33g/mol
Chemical Formula	C221H342N46O68
IUPAC Name	Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Brief Introduction

Retatrutide, a novel research peptide, is garnering attention in scientific circles for its potential applications in various research areas. It is essential to emphasize that this product is intended strictly for research purposes, and any mention of human consumption is strictly prohibited.

Key Characteristics

Retatrutide exhibits unique characteristics that make it a promising subject for in-depth research. Its structure and mode of action provide researchers with intriguing possibilities for exploring its effects in controlled laboratory settings.

Research Applications

The applications of Retatrutide in research settings are diverse. Researchers are investigating its impact on several physiological processes, aiming to uncover potential correlations and mechanisms of action.

Research Benefits

Weight Reduction and Obesity Management

Initial studies suggest that Retatrutide may play a role in weight reduction and obesity management in research models. This area of investigation could offer insights into novel pathways for addressing obesity-related concerns.

Glucose Regulation

Researchers are exploring the effects of Retatrutide on glucose regulation. Preliminary findings hint at its potential to influence glucose metabolism, sparking interest in its applications for metabolic health.

Metabolic Health Improvement

In ongoing research endeavors, Retatrutide is being scrutinized for its impact on overall metabolic health. Researchers are keen to unravel its potential benefits in addressing metabolic imbalances.

Summary

Retatrutide, a research peptide with distinctive characteristics, holds promise for various research applications. Studies centered around weight reduction, glucose regulation, and overall metabolic health are underway, offering potential avenues for further exploration in controlled research environments. It is crucial to reiterate that Retatrutide is designated for research purposes only, and any mention of human use is strictly prohibited.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., et al. (June 26, 2023). “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. [Read More].
2. Harris E. Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss. JAMA. 2023;330(4):306. doi:10.1001/jama.2023.12055. [Read More].
3. Sheila A Doggrell (2023) Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opinion on Investigational Drugs, 32:5, 355-359. [Read More].